cagrisema phase 3 results 2025 semaglutide cagrilintide obesity semaglutide cagrilintide 2024 Cagrilintide– Semaglutide in Adults with Overweight or and Type 2 Diabetes cagrilintide clinical trials results Comparative

2008 Apr;134(4):A-545

People with BMIs under 30 can be metabolically unhealthy

(R-KS) sent a bipartisan letter to the FDA flagging Hims & Hers' ad and accusing the company of misleading patients "by omitting any safety or side effect information when promoting a specific type of weight loss medication." Under federal law and regulations, FDA requires that prescription drug advertisements be truthful, not misleading, and balancedfailure to do so risks FDA enforcement action, including civil monetary penalties, Durbin and Marshall said in the letter

we know that exercise and dietary change are also particularly important in maintaining weight loss. There are also other medications authorised in Australia for weight management, such as Saxenda, which work in similar ways and deliver similar results, and Willett suggested patients ask about those and consider them first